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The past decade has witnessed major scientific and 
technological advancements, and one among them was 
molecular imaging. Today, molecular imaging 
constitutes a major trend in biomedical research and 
seems to have the potential to revolutionise life sciences. 
Molecular imaging plays a valuable role in the 
assessment of cellular targets and the response to therapy, 
differential diagnosis, prediction or selection of patients 
who will benefit from treatment, and in dosimetry for 
targeted therapy. The field of preclinical and clinical 
molecular imaging has developed simultaneously with 
molecular medicine, which holds great promise to 
provide significant healthcare benefits in the future. The 
advent of dual-modality PET/CT units is a prominent 
example of advance in molecular imaging technology. It 
offers the opportunity to modernise the practice of 
clinical oncology by improving lesion localisation and 
facilitating treatment planning for radiation therapy.  
Although dual-modality imaging systems designed 
specifically for clinical practice are a recent feature, the 
potential advantages of combining anatomical and 
functional imaging has been recognised for several 
decades by radiological scientists and physicians [1]. 
Many of the pioneers of nuclear medicine recognised 
that a radionuclide imaging system could be augmented 
by adding an external radioisotope source. This would 
acquire transmission data for anatomical correlation of 
the emission image. The conceptual designs were, 
however, never introduced in practice or implemented in 
either an experimental or a clinical setting until 
Hasegawa and colleagues (University of California, San 
Francisco) pioneered in the 1990s the development of 
dedicated SPECT/CT [2,3]. Later, Townsend and co-
workers (University of Pittsburgh) pioneered in 1998, the 
development of combined PET/CT imaging systems. 
These have the capability to record both PET emission 
and x-ray CT data for correlated functional/structural 
imaging [4,5]. Thereafter, PET/CT dual-modality 
imaging systems were introduced by the major scanner 
manufacturers for routine clinical use. According to 
market reports, over 90% of today’s PET sales are 
combined PET/CT units. This led almost all scanner 
manufacturers to opt for replacing entirely PET-only 
scanners by PET/CT. While all clinical and commercial 
dual-modality systems have been configured in the form 
of PET/CT or SPECT/CT scanners, several investigators 
proposed, implemented, and tested prototype combined 
PET/MRI imaging systems [6]. PET/MRI is a more 
challenging technology compared with PET/CT. The 
importance of this development will only be understood 
and manifest when this and other forms of dual-modality 
imaging become available in the ensuing years and are 
utilised for clinical studies of humans as well as 
biological investigations involving animal models of 
human disease. 
Since its inception, PET/CT has been advertised as a 
cutting-edge technology to influence clinicians and 
decision makers to adopt it as the new gold standard 
modality and to push scanner manufacturers to replace 
standalone PET scanners with combined PET/CT units. 
The latter is considered a questionable choice by some of 
the pioneers in this field, with whom the author concurs 
[7]. The marketing strategy of vendors supported by 
many scientists aiming at disseminating PET/CT 
technology in the clinic is that the added value of 
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combined units is well-established and represents the 
ultimate
 solution for image co-registration. According to 
them, this solution enables appropriate combination of 
imaging technologies to
  yield useful anato-molecular 
imaging fusion [8]. The bottom line is that although 
PET/CT has been accepted commercially, the clinical 
benefits and the need for this technology remains 
controversial [9,10]. These issues are still being debated 
[7,11]. While hybrid PET/CT has many interesting 
features and offers several advantages compared with 
software
 approaches of image co-registration for patient 
diagnosis and image-guided radiation therapy, it is often 
argued that combined PET/CT is not the ultimate
 
solution for image co-registration [12,13]. It is also 
possibly not considered a major breakthrough that 
revolutionised the paradigm
 of medical imaging [11]. 
The use of the noise-free CT data for attenuation 
correction of PET images has indisputably several 
virtues compared with conventional radionuclide-based 
transmission scanning. It should, however, be recognised 
that its clinical benefits have not been unequivocally 
demonstrated and should be carefully documented by 
investigators for wider acceptance. The key point is that 
many PET procedures do not require a diagnostic quality 
CT, and radionuclide-based transmission scanning would 
be a better option than low-dose CT protocols. It is still 
too early to claim that
 transmission scanning devices are 
obsolete for PET/CT, and that CT-based attenuation 
correction should be the gold standard on these systems 
[14]. In my opinion, transmission scanning has a genuine 
role and remains an appealing alternative until all the 
problems associated with CT-based attenuation 
correction are resolved through research [15]. 
It is the responsibility of clinical scientists and 
medical physicists providing support to clinical PET 
facilities and involved in today’s biomedical imaging 
research enterprise to debate on important issues about 
the introduction of new technologies. They must educate 
and advise clinical end users who often make choices 
under the influence of advertisements and the pressure of 
competitors. Any new technology should be assessed 
carefully with respect to benefits conveyed to patients. I 
share the opinion of the same pioneer mentioned above 
[7] and emphasise that we clearly need a worldwide 
debate involving all potential users of this technology on 
how best to adapt to novel information and technological 
progress. We urgently need large-scale studies to 
demonstrate the clinical benefits of PET/CT and, more 
importantly, to define where PET alone is needed and 
where PET/CT is needed. 
PET/CT is poised to advance the application of 
molecular diagnosis in oncology, neurology, cardiology, 
infectious diseases, and other types of disease. 
Nevertheless, PET/CT is obviously not the only major 
non-invasive tool
 for the assessment of human disease. 
New technologies, such as, high-field MRI and 
bioluminescent
 and fluorescent imaging have blurred the 
artificial
 distinction that, in the past, set nuclear medicine 
as a "functional"
  rather than "anatomic" imaging 
modality [16]. PET/CT definitely maintains
 an exclusive 
standing in the delivery of targeted therapies, but its
 
superior picomolar sensitivity is being challenged by 
competing
 technologies, such as those using ultra small 
superparamagnetic contrast
 agents [17]. 
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